Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2013 07:30 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers

MANCHESTER, NH--(Marketwire - Jan 28, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
December 19, 2012 07:30 ET | Source: Boston Therapeutics

Boston Therapeutics Approved in France to Initiate a Clinical Trial With SUGARDOWN(R) in Patients With Type II Diabetes

MANCHESTER, NH--(Marketwire - Dec 19, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to...
November 29, 2012 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics to Present Corporate Update at the SeeThruEquity Smallcap & Microcap Investor Summit

MANCHESTER, NH--(Marketwire - Nov 29, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to treat...
November 14, 2012 15:39 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Third Quarter and Nine Months 2012 Financial Results

MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) SUGARDOWN® sales increased approximately 700% in the first nine months...
November 14, 2012 08:15 ET | Source: Boston Therapeutics

Boston Therapeutics' Newly Appointed Chief Operating Officer Invests $625,000 in the Company's S-1 Financial Offering

MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
November 13, 2012 08:15 ET | Source: Boston Therapeutics

Boston Therapeutics Names Jonathan B.Rome Chief Operating Officer

MANCHESTER, NH--(Marketwire - Nov 13, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
October 04, 2012 07:01 ET | Source: Boston Therapeutics

Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes

MANCHESTER, NH--(Marketwire - Oct 4, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and...
September 24, 2012 11:51 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics Announces Filing of S-1 Registration Statement

MANCHESTER, NH--(Marketwire - Sep 24, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
August 14, 2012 13:48 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics Reports Second Quarter and Six Months 2012 Financial Results

MANCHESTER, NH--(Marketwire - Aug 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate...
July 16, 2012 07:00 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics to Present Corporate Update at the SeeThruEquity Microcap Investor Forum

MANCHESTER, NH--(Marketwire - Jul 16, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE)(OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to...